" class="no-js "lang="en-US"> Gerhard Compion - Medtech Alert
Monday, September 08, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Gerhard Compion

Gerhard Compion

About Gerhard Compion

I have more than twelve years of experience in Medical Affairs and consider myself commercially aware yet believe ethics and compliance with regulations is also important. I enjoy developing medical strategy and executing a medical plan, particularly when its pre launch or launch product activities.

After qualifying in South Africa and working as a doctor in SA, Namibia and the NHS, I joined the pharmaceutical industry in 2004. My experience has been in Diabetes, HRT, Gout, Renal and Cardiovascular Medicine, Aesthetic Medicine and Urology. I have been a final signatory for 11 years

Related Story

Diseases

 Novartis Awarded Promising Innovative Medicine Designation for Targeted Radioligand Theragnostics in Prostate Cancer | Pharmtech Focus

Novartis Awarded Promising Innovative Medicine Designation for Targeted Radioligand Theragnostics in Prostate Cancer

October 20 2021

Novartis today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Promising […]